An observational study in Pulmonary Hypertension, sponsored by First Affiliated Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by First Affiliated Hospital of Fujian Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.
Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 10 that started in 2025, is one of 36 observational ones, reaches primary completion later than 25 of the 35 other live ones, and was the 77th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Xiamen Cardiovascular Hospital, Xiamen University · Sites in China
Ages 18–80
Beijing Continent Pharmaceutical Co, Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 100 across the 47 interventional studies, 750 across the 36 observational. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 85 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.
First Affiliated Hospital of Fujian Medical University has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension, Pulmonary with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT06023134Jingyi RenClinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure | 2027-09-01 |
| NCT06980584Beijing Chao Yang HospitalStudy on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Hypertension, Pulmonary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.
This is a prospective, observational cohort study designed to investigate dynamic risk prediction in patients diagnosed with pulmonary hypertension (PH). The study will collect multimodal clinical data-comprising imaging (echocardiography, cardiac MRI, PET-MR), electrocardiographic parameters, blood-based biomarkers, and demographic and clinical information-at baseline and follow-up intervals. The core objective is to develop a data fusion-based prognostic model capable of predicting adverse outcomes such as hospitalization, functional deterioration, or mortality. Machine learning methods will be employed to identify key predictive features. The model will be validated internally and externally across different subgroups. The study seeks to inform individualized risk-based decision-making and advance precision screening in PH care.
In addition, biospecimens will be collected to support comprehensive multi-omics profiling. Whole blood, serum, plasma, urine, and stool samples will be obtained and processed using standardized protocols. Blood-derived samples will be used for genomic, proteomic, metabolomic, and microRNA analyses; urine specimens will support metabolomic and renal biomarker assays; and stool samples will be used for gut microbiome sequencing. All biospecimens will be stored in a secure biobank and linked with clinical, imaging, and longitudinal follow-up data using de-identified subject codes to enable integrated multimodal analyses and facilitate future exploratory investigations of disease mechanisms and biomarker discovery.
Health economic evaluation, including cost-effectiveness and budget impact analyses, will be conducted using collected data on healthcare resource utilization, direct medical costs, and clinical outcomes to inform future policy and reimbursement decision-making.
The study population includes adult patients (≥18 years) undergoing transthoracic echocardiography. Participants with a pulmonary artery systolic pressure (PASP) ≥35 mmHg on echocardiography will be included as suspected pulmonary hypertension cases. This cohort represents a real-world population at risk for or with early-stage pulmonary hypertension, suitable for developing dynamic risk prediction models based on multimodal data integration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study includes a prospective observational cohort of patients with suspected pulmonary hypertension (PH), identified by transthoracic echocardiography (TTE) showing a pulmonary artery systolic pressure (PASP) ≥35 mmHg. No experimental intervention will be applied. Participants will undergo comprehensive data collection, including echocardiography, cardiac magnetic resonance imaging (CMR), electrocardiography (ECG), laboratory testing, and biospecimen sampling (blood, urine, and stool). Follow-up will occur every 6 months for up to 3 years to record clinical outcomes and support the development of a dynamic, multimodal risk prediction model based on artificial intelligence.
Time to clinical worsening
Defined as any of the following: hospitalization for PH, escalation of therapy, 6MWD decrease \>15%, WHO-FC worsening, or death. Measured from baseline.
Time frame: Up to 36 months
All-cause mortality
Death from any cause during follow-up, as confirmed by medical records or death registry.
Time frame: Up to 36 months
Composite risk score performance (AUC)
Area under the ROC curve for the multimodal model predicting adverse outcomes.
Time frame: At baseline and follow-up every 6 months
Changes in NT-proBNP levels
Evaluate biomarker dynamics and predictive value.
Time frame: Baseline, 6, 12, 24, 36 months
Hospitalization rate for PH-related causes
Frequency of hospital admissions due to PH complications.
Time frame: Up to 36 months
Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) Measured by Transthoracic Echocardiography
TAPSE (mm) will be measured via transthoracic echocardiography to evaluate longitudinal right ventricular systolic function over time.
Time frame: Baseline, 6, 12, 24, 36 months
Change in Right Ventricular Diameter Measured by Transthoracic Echocardiography
Right ventricular internal diameter (mm) will be assessed by echocardiography as an indicator of RV structural remodeling.
Time frame: Baseline, 6, 12, 24, 36 months
Change in Right Ventricular Fractional Area Change (RVFAC) Measured by Transthoracic Echocardiography
RVFAC (%) will be calculated as the percentage change in RV area between end-diastole and end-systole to assess systolic function.
Time frame: Baseline, 6, 12, 24, 36 months
Change in Right Ventricular Ejection Fraction (RVEF) Measured by Cardiac Magnetic Resonance Imaging
RVEF (%) will be quantified using cardiac magnetic resonance imaging to evaluate global systolic function.
Time frame: Baseline, 6, 12, 24, 36 months
Change in Right Ventricular End-Diastolic Volume Measured by Cardiac Magnetic Resonance Imaging
Right ventricular end-diastolic volume (mL) will be measured by CMR to assess structural remodeling over time.
Time frame: Baseline, 6, 12, 24, 36 months
Change in Right Ventricular Mass Measured by Cardiac Magnetic Resonance Imaging
Right ventricular mass (grams) will be measured by CMR as an index of ventricular hypertrophy and remodeling.
Time frame: Baseline, 6, 12, 24, 36 months
Change in Right Ventricular FAPI Uptake (SUVmean) Measured by FAPI PET-MR
tandardized uptake value mean (SUVmean) of FAPI in the right ventricular free wall will be quantified using PET-MR imaging to assess fibroblast activation and myocardial fibrotic activity over time in patients with pulmonary hypertension.
Time frame: Baseline, 12, 24, and 36 months
Change in Right Ventricular FAPI Uptake (SUVmax) Measured by FAPI PET-MR
Maximum standardized uptake value (SUVmax) of FAPI in the right ventricle will be measured via PET-MR as an indicator of peak regional fibroblast activation.
Time frame: Baseline, 12, 24, and 36 months
Change in Right Ventricular FAPI Uptake Ratio Relative to Left Ventricle (SUVratio) Measured by FAPI PET-MR
The ratio of right ventricular to left ventricular myocardial FAPI uptake (SUVmean RV/SUVmean LV) will be calculated as a normalized index of right ventricular fibrotic remodeling.
Time frame: Baseline, 12, 24, and 36 months
Longitudinal changes in health-related quality of life (HRQoL) among patients with suspected or confirmed pulmonary hypertension
Health-related quality of life (HRQoL) will be assessed using validated instruments such as the EQ-5D-3L and/or the emPHasis-10 questionnaire, both commonly used in pulmonary hypertension research. The emPHasis-10 is a disease-specific, patient-reported outcome measure developed for individuals with pulmonary hypertension, covering domains such as breathlessness, fatigue, social limitation, and psychological burden. Changes in HRQoL scores will be evaluated over time and correlated with clinical events (e.g., hospitalization, WHO functional class deterioration), imaging parameters (e.g., RV function), biomarkers (e.g., NT-proBNP), and model-predicted risk strata. Analyses will include repeated measures ANOVA or mixed-effects modeling to examine within-subject longitudinal chan
Time frame: Baseline, 6, 12, 24, and 36 months
Area Under the ROC Curve (AUC) of the Multimodal Risk Prediction Model
The area under the receiver operating characteristic curve (AUC) will be calculated to evaluate the discrimination performance of the multimodal dynamic risk prediction model for adverse outcomes.
Time frame: Baseline, 12, 24, 36 months
Harrell's Concordance Index (C-index) of the Multimodal Risk Prediction Model
The concordance index (C-index) will be computed to assess the predictive accuracy of the multimodal risk prediction model.
Time frame: Baseline, 12, 24, 36 months
Calibration Slope of the Multimodal Risk Prediction Model
Calibration slope will be estimated to measure agreement between predicted and observed risks in the dynamic risk prediction model.
Time frame: Baseline, 12, 24, 36 months
Net Benefit Derived from Decision Curve Analysis of the Multimodal Risk Prediction Model
Net benefit will be calculated using decision curve analysis to evaluate the clinical usefulness of the multimodal risk prediction model in guiding clinical decision-making.
Time frame: Baseline, 12, 24, 36 months
Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular Ejection Fraction (RVEF)
NT-proBNP concentration will be measured in plasma using a standardized immunoassay (pg/mL). Pearson correlation coefficients (r) will be calculated between NT-proBNP levels and right ventricular ejection fraction (RVEF, %) measured by cardiac MRI. Unit of Measure: Correlation coefficient (r)
Time frame: Baseline, 6, 12, 24, and 36 months
Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular End-Diastolic Volume (RVEDV)
NT-proBNP concentration measured by immunoassay (pg/mL) will be correlated with right ventricular end-diastolic volume (mL) assessed by cardiac MRI. Pearson correlation coefficients (r) will be calculated at each follow-up time point. Unit of Measure: Correlation coefficient (r)
Time frame: Baseline, 6, 12, 24, and 36 months
Correlation between NT-proBNP Concentration (pg/mL) and TAPSE
NT-proBNP levels (pg/mL) obtained by immunoassay will be correlated with tricuspid annular plane systolic excursion (TAPSE, mm) measured on transthoracic echocardiography using Pearson correlation. Unit of Measure: Correlation coefficient (r)
Time frame: Baseline, 6, 12, 24, and 36 months
Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular Longitudinal Strain
NT-proBNP values (pg/mL) will be correlated with right ventricular longitudinal strain (%) measured by speckle-tracking echocardiography. Pearson correlation coefficients (r) will be reported. Unit of Measure: Correlation coefficient (r)
Time frame: Baseline, 6, 12, 24, and 36 months
Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular Fractional Area Change (RVFAC)
Plasma NT-proBNP level (pg/mL) will be correlated with right ventricular fractional area change (RVFAC, %) measured using echocardiography, and correlation coefficients (r) will be calculated over time. Unit of Measure: Correlation coefficient (r)
Time frame: Baseline, 6, 12, 24, and 36 months
Association between Baseline NT-proBNP Concentration and Time to Clinical Worsening
Baseline plasma NT-proBNP levels (pg/mL), measured using a standardized immunoassay, will be analyzed using Cox proportional hazards models to assess their association with time to clinical worsening, defined as hospitalization for pulmonary hypertension, WHO functional class deterioration, or death. Unit of Measure: Hazard ratio (HR)
Time frame: Up to 36 months
Association between Baseline NT-proBNP Concentration and Model-Predicted Risk Categories
Baseline NT-proBNP concentration (pg/mL), measured using a standardized immunoassay, will be analyzed using multinomial or logistic regression models to evaluate its association with model-predicted risk categories (e.g., low-, intermediate-, and high-risk strata) generated by the multimodal dynamic risk prediction model. Unit of Measure: Odds ratio (OR)
Time frame: Baseline, 6, 12, 24, and 36 months
Plan to share: Yes — De-identified individual participant data, including demographic information, clinical characteristics, imaging parameters (echocardiography and CMR), ECG data, laboratory test results, biospecimen profiles (e.g., biomarkers, multi-omics), and follow-up outcomes, will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: IPD will be made available beginning 24 months after the primary study completion date and remain accessible for up to 24 months.
Access criteria: Qualified researchers with a scientifically sound proposal may request access to the data. Requests will be evaluated by the study steering committee. Approved users must sign a data use agreement ensuring compliance with privacy, ethical, and scientific standards.
Data sharing details ↗ · www.fjmu.edu.cn
Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 36 months is below that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Fujian Medical University